Bibliografía del artículo
1. Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 1999; 341:1276-1283.
2. Piskorz D, Robiolo O, Citta N y cols. Fenotipos Ventriculares en Hipertensión Arterial. Rev Fed Arg Cardiol 2000; 29(Suplemento 1):116.
3. Chien KR, Zhu H, Knowlton KU y cols. Transcriptional regulation during cardiac growth and development. Annual Review of Physiology 1993; 55:77-95.
4. Simpson PC, Long CS, Waspe LE, Henrich CJ, Ordahl CP. Transcription of early developmental isogenes in cardiac myocite hypertrophy. J Mol Cell Cardiol 1989; 21:(Suppl. V):79 - 89.
5. Chien KR, Knowlton KU, Zhu H, Chien S. Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptative physiologic response. FASEB J 1991; 5:3037-3046.
6. Thorburn A, Thorburn J, Chen SY y cols. HRas - dependent pathways can activate morphological and genetic markers of cardiac muscle cell hypertrophy. J Biol Chem 1993; 268:2244-2249.
7. Hunter JJ, Tanaka N, Rockman HA, Ross J Jr, Chien Kr. Ventricular expression of a MLC - 2v - ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem 1995; 270:35173-35178.
8. Xia Z, Dickens M, Raingeaud J, Davis BJ, Greenberg ME. Opposing effects of ERK and JNK - p38 MAP kinases on apoptosis. Science 1995; 270:1326-1331.
9. Wang Y, Huang S, Sah VP y cols. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen - activated protein kinase family. J Biol Chem 1998; 273:2161-2168.
10. Wang Y, Su B, Sah VP y cols. Cardiac Hypertrophy induced by mitogen - activated protein kinase 7, a sepcific activator for c - Jun NH2 - terminal kinase in ventricular muscle cell. J Biol Chem 1998; 273:5423-5426.
11. Sugihara N, Genda A, Shimizu N y col: Diastolic dysfunction and its relation to myocardial fibrosis in essential hypertension. J Cardiol 1988; 18:353-361.
12. Kook H, Lepore JJ, Gitler AD y col: Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J Clin Invest 2003; 112:863-871.
13. Kiss E, Jakab G, Kranias EG, Edes I. Thyroid hormon - induced alterations in phospholamban protein expression: regulatory effects on sarcoplásmico reticulum Ca2++ transport and myocardial relaxation. Circulation Research 1994; 75:245-257.
14. Ojama K, Klien I, Sabet A, Steinberg SF. Changes in adenyl cyclase isoforms as a mechanism fot thyroid hormone modulation of cardiac B adrenergic receptor reponsiveness. Metabolism 2000; 49:275-279.
15. Milano CA, Dolber PC, Rockman HA y cols. Myocardial expresión of a constitutively active alpha 1B - adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci USA 1994; 91:10109-10113.
16. La Morte VJ, Thorburn J, Absher D y cols. Gq - and ras - dependent pathways mediate Hypertrophy on neonatal rat ventricular myocites following alpha 1 - adrenergic stimulation. J Biol. Chem 1994; 269:13490-13496.
17. Adam JW, Sakata Y, Davis MG y cols. Enhanced Galphaq signaling: a common pathway mediates cardia hypertrophy and apoptotic heart failure. Proc Natl Acad Sci USA 1998; 95:10140-10145.
18. Piskorz D, Citta L, Citta N y col: Heart rate variability and left ventricle hypertrophy. J Hypertension 2004; 22 (Suppl 1):154S.
19. Schunkert H, Hense HW, Homer SR y col: Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med 1994; 330:1634-1638.
20. Brilla CG, Pick R, Tan LB y col: Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990; 647:1355-1364.
21. Chapman D, Weber KT, Eghbali M: Regulation of fibrillar collagen types I and III and basement membrane type IV collagen gene expression in pressure overloaded rat myocardium. Circ Res 1990; 67:787-794.
22. Robert V, Silvestre JS, Charlemagne J y col: Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension 1995; 26:971-978.
23. Fulerton MJ, Funder JW: Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res 1994; 28:1863-1867.
24. Malmqvist K, Ohman KP, Lind L y col: Relationships between left ventricular mass and the renin-angiotensin system, catecholamines, insulin and leptin. J Intern Med 2002; 252:430-439.
25. Weber KT: Aldosterone in congestive heart failure. N Engl J Med 2001; 345:1689-1697.
26. Rocha R, Rudolph AR, Frierdich GE y col: Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol (Heart Circ Physiol) 2002; 283:H1802-H1810.
27. Schlaich MP, Schobel HP, Hilgers K y col: Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am J Cardiol 2000; 85:1199-1206.
28. Grandi AM, Imperiale D, Santillo R y col: Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension 2002; 40:647-652.
29. Burnett JC Jr: Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens 1999; 17 (Suppl):S37-S43.
30. Yamamoto S, Sawada K, Shimomura H, Kawamura K, James TN. On the nature of cell death during remodeling of hypertrophied human myocardium. J Mol Cell Cardiol 2000; 32:161-175.
31. Hamet P, Richard L, Dam TV y cols. Apoptosis in target organs in hypertension. Hypertension 1995; 26:642-648.
32. Li Z, Bing OHL, Long X, Robinson KG, Lakatta EG. Increased cardiomyocite apoptosis during the transition to heart failure in the spontanepusly hypertensive rat. Am J Physiol 1997; 272:2313H-2319H.
33. Diez J, Panizo A, Hernández M y cols. Cardiomyocite apoptosis and cardiac angiotensin - converting enzyme in spotaneously hypertensive rats. Hypertension 1997; 30:1029-1034.
34. Diez J, Fortuño Ma, Ravassa S. Apoptosis in hypertensive heart disease. Curr Opin Cardiol 1998; 13:317-325.
35. Gonzalez A, López B, Ravassa S y cols. Stimulation of cardiaca apoptosis in essential hypertension. Potential role of angiotensin II. Hypertension 2002; 39:75-80.
36. Ravassa S, Fortuño MA, González A y cols. Mechanisms of increased susceptibility to angiotensin II - induced apoptosis in ventricular cardiomyocites of spontaneously hypertensive rats. Hypertension 2000; 36:1065-1071.
37. Liu JJ, Peng I, Bradley CJ y cols. Increased apoptosis in the heart of genetic hypertension, associated with increased fibroblasts. Cardiovasc Res 2000; 45:729-735.
38. Yamada T, Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA 1996; 93:156-160.
39. Sadoshima J, Izumo S. Molecular characterization of angiotensin II - induced Hypertrophy of cardiac myocites and hyperplasia of cardiac fibroblast: critical role of AT1 receptor subtype. Circ Res 1993; 73:413-423.
40. Tsutsumi Y, Matsubara H, Ohkubo N y cols. Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. Circ Res 1998; 83:1035-1046.
41. Nishida K, Yamaguchi O, Hirotani S y cols. p38alfa mitogen - activated protein kinase plays a critical role in cardiomyocite survival but not in cardiac hypertrophic growth in response to pressure overload. J Mol Cell Biol 2004; 24:10611-10620.
42. Braz JC, Bueno OF, Liang Q y cols. Targeted inhibition of p38 MAPK promotes hupertrophic cardiomyopathy thorough upregulation of calcineurin - NFAT signaling. J Clin Invest 2003; 111:1475-1486.
43. Communal C, Colucci WS, Singh K. p38 Mitogen - activated protein kinase pathway protects adult rat ventricular myocites against beta adrenergic receptor - stimulated apoptosis: evidence for Gi - dependent activation. J Biol Chem 2000; 275:19395-19400.
44. Wang I, Huang S, Sah VP y cols. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen - activated protein kinase family. J Biol Chem 1998; 273:2161-2168.
45. Zechner D, Thuerhauf DJ, Hanford DS y cols. A role for the p38 mitogen - activated protein kinase pathway in myocardial cell growth, sarcomeric organization, and cardiac - specific gene expression. J Cell Biol 1997; 139:115-127.
46. Singh K, Communal C, Sawyer DB, Colucci WS. Adrenergic regulation of myocardial apoptosis. Cardiovasc Res 2000; 45:713-719.
47. Hoover HE, Thuerhauf DJ, Martindale JJ, Glembotski CG. Alpha B - crystallin gene induction and phosphorylation by MKK6 - activated p38: a potential role for alpha B - crystalline as a target of the p38 branch of the cardiac stress response. J Biol Chem 2000; 275:23825-23833.
48. Fortuño MA, Ravassa S, Etayo JC, Diez J. Overexpression of Bax - alpha protein and enhanced apoptosis in the left ventricle of spontaneously hypertensive rats: effects of AT1 blockade with losartan. Hypertension 1998; 32:280-286.
49. Kajstura J, Cigola E, Malhotra A y cols. Angiotensin II induces apoptosis of adult ventricular myocites in vitro. J Mol Cell Cardiol 1997; 29:859-870.
50. Leri A, Claudio P, Li Q y cols. Stretch - mediated release of angiotensin II induces myocites apoptosis by activating p53 that enhances the local renin - angiotensin system and decreases the Bcl - 2 to - Bax protein ratio in the cell. J Clin Invest 1998; 101:1326-1342.
51. Young LH, Renfu Y, Russell R y cols. Low flow ischemia induces translocation of canine heart Glut 4 and Glut 1 glucose transporters to sarcolemma in vivo. Circulation 1997; 95:415-422.
52. Sun D, Nguyen N, DeGrado TR, Schwaiger M, Brosius FC. Ischemia induces translocation of the insulin - responsive glucose transporter GLUT 4 to the plasma membrane of cardiac myocites. Circulation 1994; 89:793-798.
53. Kakzmarczyk SJ, Andrikopoulos S, Favaloro J y cols. Threshold effects of glucose transporter - 4 ( GLUT4 ) deficiency on cardiac glucose uptake and development of hypertrophy. J Mol Endocrinol 2003; 31:449-450.
54. Tellería J, Piskorz D, Citta N y cols. Left ventricular geometry in hypertensive patients: different ventricles or different patients. Clinical and Experimental Hypertension 2004; 26:94.
55. Pozzi E, Piskorz D, Citta L y cols. Curva de Tolerancia Glúcida e Hipertrofia Ventricular izquierda. Rev Fed Arg Cardiol 2003; 32(Suplemento 2):29.
56. Bonelli J, Piskorz D, Citta L y cols. En Hipertensión Arterial la presencia de Síndrome Metabólico incrementa el riesgo de lesión en órgano blanco. Rev Fed Arg Cardiol 2004; 33(Supl.1):40.
57. Bonelli J, Piskorz D, Citta L y cols. En pacientes hipertensos arteriales el número de componentes del Síndrome Metabólico incrementa el daño en órgano blanco. Rev Fed Arg Cardiol 2004; 33(Supl.1):40.
58. Hayward CS, Webb CM, Collins P. Effect of sex hormones on cardiac mass. Lancet 2001; 357:1354-1356.
59. Marsh JD, Lebmann MH, Ritchie RH y cols. Androgen receptors mediate hypertrophy in cardiac myocites. Circulation 1998; 98:256-261.
60. Morano I, Gerstner J, Ruegg JC y cols. Regulation of myosin heavy chain expression in the hearts of hypertensive rats by testosterone. Circ Res 1990; 66:1585-1590.
61. Thum T, Borlak J. Cytochrome p450 mono - oxygenase gene expression and protein activity in cultures of adults cardyomicytes of the rat. Br J Pharmacol 2000; 130:1745-1752.
62. Thum T, Borlak J. Testosterone, cytochrome p450, and cardiac hypertrophy. FASEB J 2002; 16:1537-1549.
63. Kinugawa K, Yonekura K, Ribeiro RCJ y cols. Regulation of thyroid hormone receptor isoforms in physiological and pathological cardiac hypertrophy. Circ Res 2001; 89:591-598.